希腊单中心司库奇尤单抗治疗斑块状银屑病真实世界数据:疗效、安全性、药物生存及持续最佳应答预测因素
该78周单中心回顾性研究纳入85例中重度斑块状银屑病患者,评估司库奇尤单抗的真实世界疗效、安全性和药物生存率。第52周和78周绝对PASI≤3分别达73%和83%,药物生存率79.1%,高BMI和≥3种合并症降低第78周达到PASI≤3的可能性。
要点
- 司库奇尤单抗在真实世界中第78周绝对PASI≤3达83%,PASI100达45.3%。
- 第78周药物生存率79.1%,因疗效丧失停药者占10.4%。
- 高BMI和≥3种合并症是第78周PASI≤3应答的负性预测因素。
核心结论
- 司库奇尤单抗在真实世界队列中显示持续高疗效和可接受的安全性。
- 高BMI或多种合并症患者中PASI≤3应答的持续性较低。
研究设计与样本
- 78周、单中心、回顾性研究,共纳入85例中重度斑块状银屑病患者(75.3%男性,平均年龄48.6岁)。
主要发现
- 第52周和78周绝对PASI≤3分别达73%和83%。
- 第52周PASI 75/90/100分别为71.6%、50.8%、40.3%,第78周分别为73.6%、64.2%、45.3%。
- 第52周和78周中位绝对PASI分别为0.9和0.6,IGA 0/1应答率分别为72%和83%。
- 第78周药物生存率79.1%,17.9%患者平均41.7周后停药,主要因疗效丧失(10.4%)。
- 27%患者发生不良事件,无关键安全性问题。
关键数值与推荐
- 多因素分析显示,高BMI降低第78周达到PASI≤3的机会[OR 0.78(95%CI 0.64-0.97),P=0.024]。
- ≥3种合并症降低第78周达到PASI≤3的机会[OR 0.045(95%CI 0.002-0.83),P=0.037]。
临床怎么用
- 司库奇尤单抗可用于中重度斑块状银屑病的长期治疗,但高BMI或多种合并症患者需关注应答持续性。
局限性
- 单中心回顾性设计,样本量有限(85例),有效性数据为观察数据分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Few studies have investigated the long-term outcomes of secukinumab in real-life psoriasis treatment where diverse patient profiles require a personalized approach. OBJECTIVES: To determine long-term performance of secukinumab in moderate-to-severe plaque psoriasis, and identify potential clinical factors predictive of sustained optimal response under real-world conditions. METHODS: In this 78-week, single-centre, retrospective study, effectiveness, safety and drug survival of secukinumab were evaluated. Effectiveness data are reported as observed. Co-primary endpoints were absolute Psoriasis Area and Severity Index (PASI) ≤3 at week 4, 16, 52, 78, and clinical predictors of PASI ≤3 and PASI100 responses at week 52 and 78. RESULTS: A total of 85 patients (75.3% male; mean age 48.6 years) were included. Absolute PASI ≤3 was achieved in 73% and 83% of patients at week 52 and 78, respectively. PASI 75/90/100 responses at week 52 (71.6%, 50.8%, and 40.3%, respectively) were sustained at week 78 (73.6%, 64.2%, and 45.3%, respectively). Median absolute PASI remained low at week 52/78 (0.9/0.6, respectively), while mean absolute PGA also sustained low (0-1) values after 16-78 weeks. Investigator's Global Assessment 0/1 response rate was maintained by week 52/78 (72/83%, respectively). The drug survival rate of secukinumab at week 78 was 79.1%. Treatment was discontinued in 17.9% of patients after an average of 41.7 weeks, mainly due to loss of effectiveness (10.4%). A total of 27% experienced adverse events, without critical safety concerns. Based on multivariate analysis, advanced body mass index (BMI) and presence of ≥3 comorbidities decreased the chance of achieving PASI ≤3 at week 78 [OR (95% CI) 0.78 (0.64-0.97); P = 0.024, and OR (95% CI) 0.045 (0.002-0.83); P = 0.037, respectively]. CONCLUSIONS: Secukinumab showed consistently high effectiveness in this real-life cohort, with an acceptable safety profile. Over time, persistence of PASI ≤3 response appears to be lower in patients with high BMI or multiple comorbidities.
引用
- Rompoti N, Sidiropoulou P, Panagakis P, et al. Real-world data from a single Greek centre on the use of secukinumab in plaque psoriasis: effectiveness, safety, drug survival, and identification of patients that sustain optimal response. J Eur Acad Dermatol Venereol. 2020. PMID: 31953892. doi:10.1111/jdv.16202
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。